Inovio Pharmaceuticals Stock Short Ratio
| INO Stock | USD 1.47 0.04 2.80% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Inovio Pharmaceuticals' long-term financial health and intrinsic value.
Inovio | Short Ratio | Build AI portfolio with Inovio Stock |
Inovio Pharmaceuticals Company Short Ratio Analysis
Inovio Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Inovio Pharmaceuticals Short Ratio | 1.95 X |
Most of Inovio Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inovio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inovio Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Inovio Pharmaceuticals is extremely important. It helps to project a fair market value of Inovio Stock properly, considering its historical fundamentals such as Short Ratio. Since Inovio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inovio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inovio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Inovio Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Inovio Pharmaceuticals has a Short Ratio of 1.95 times. This is 50.0% lower than that of the Biotechnology sector and 73.68% lower than that of the Health Care industry. The short ratio for all United States stocks is 51.25% higher than that of the company.
Inovio Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inovio Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inovio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Inovio Pharmaceuticals by comparing valuation metrics of similar companies.Inovio Pharmaceuticals is currently under evaluation in short ratio category among its peers.
Inovio Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inovio Pharmaceuticals from analyzing Inovio Pharmaceuticals' financial statements. These drivers represent accounts that assess Inovio Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inovio Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.0B | 372.3M | 49.7M | 44.7M | 42.5M | |
| Enterprise Value | 1.2B | 1.0B | 358.0M | (53.9B) | (62.0B) | (58.9B) |
Inovio Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Inovio Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inovio Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inovio Pharmaceuticals' value.| Shares | Goldman Sachs Group Inc | 2025-03-31 | 130.5 K | Gmt Capital Corp | 2025-03-31 | 126.1 K | Nuveen, Llc | 2025-03-31 | 103.3 K | Fmr Inc | 2025-03-31 | 100.7 K | Charles Schwab Investment Management Inc | 2025-03-31 | 98.5 K | Bank Of New York Mellon Corp | 2025-03-31 | 75.4 K | Aqr Capital Management Llc | 2025-03-31 | 73.6 K | Two Sigma Investments Llc | 2025-03-31 | 72.4 K | Xtx Topco Ltd | 2025-03-31 | 66.2 K | Deep Track Capital, Lp | 2025-03-31 | 3.1 M | Blackrock Inc | 2025-03-31 | 2.3 M |
Inovio Fundamentals
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (383.37) % | ||||
| Current Valuation | 16.04 M | ||||
| Shares Outstanding | 50.96 M | ||||
| Shares Owned By Insiders | 0.53 % | ||||
| Shares Owned By Institutions | 27.13 % | ||||
| Number Of Shares Shorted | 5.99 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 257.41 X | ||||
| Revenue | 217.76 K | ||||
| Gross Profit | (70.51 M) | ||||
| EBITDA | (103.95 M) | ||||
| Net Income | (107.25 M) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 11.87 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 1.40 X | ||||
| Cash Flow From Operations | (104.08 M) | ||||
| Short Ratio | 1.95 X | ||||
| Earnings Per Share | (3.15) X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 134 | ||||
| Beta | 1.32 | ||||
| Market Capitalization | 72.87 M | ||||
| Total Asset | 113.2 M | ||||
| Retained Earnings | (1.73 B) | ||||
| Working Capital | 62.5 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
| Net Asset | 113.2 M |
About Inovio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Inovio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Inovio Stock
| 0.7 | VERV | Verve Therapeutics Earnings Call This Week | PairCorr |
| 0.64 | VANI | Vivani Medical | PairCorr |
| 0.6 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.55 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.54 | DVAX | Dynavax Technologies | PairCorr |
The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.
The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Inovio Pharmaceuticals Piotroski F Score and Inovio Pharmaceuticals Altman Z Score analysis. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.15) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.